Novartis(NVS) - 2022 Q4 - Earnings Call Presentation

INNOVATION Improvements across a range of other secondary endpoints: Increasing Hb, reducing patient-reported fatigue and reticulocyte count, maintaining low LDH Duration Company overview Financial review 2023 priorities Appendix Iptacopan 200mg BID1 Met primary endpoint of proportion of patients achieving a sustained increase in Hb of ≥ 2g/dL, in the absence of transfusions, at 24 weeks ... and showed clinically meaningful increases in Hb levels for treatment-naive adult patients with PNH Company overview ...